We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+50.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$1.1B
AUM Growth
+$345M
(+45%)
Cap. Flow
+$47.4M
Cap. Flow
% of AUM
4.29%
Top 10 Holdings %
Top 10 Hldgs %
64.76%
Holding
67
New
13
Increased
15
Reduced
13
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$29.8M |
| 2 |
Immix Biopharma
IMMX
|
+$21.8M |
| 3 |
MeiraGTx Holdings
MGTX
|
+$14.2M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$14.1M |
| 5 |
Verastem
VSTM
|
+$8.71M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perspective Therapeutics
CATX
|
+$19.5M |
| 2 |
Harrow
HROW
|
+$16.1M |
| 3 |
SNWV
SANUWAVE Health Inc
SNWV
|
+$10.5M |
| 4 |
JBIO
Jade Biosciences
JBIO
|
+$5.89M |
| 5 |
Liquidia Corp
LQDA
|
+$5.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
CG Oncology
CGON
$6.59B
| $1.26M | 0.11% |
17,789
-77,011
| -81% | -$5.03M |
|
52
Biohaven
BHVN
$2.33B
| $1.16M | 0.11% |
+77,915
| New | +$839K |
|
53
Atea Pharmaceuticals
AVIR
$430M
| $1.09M | 0.1% |
235,000
-87,600
| -27% | -$436K |
|
54
Pasithea Therapeutics
KTTA
$18.7M
| $1.06M | 0.1% |
+2,050,000
| New | +$1.41M |
|
55
ADC Therapeutics
ADCT
$146M
| $749K | 0.07% |
+700,000
| New | +$2.04M |
|
|
OKYO
56
OKYO Pharma
OKYO
$87.6M
| $563K | 0.05% |
+375,204
| New | +$601K |
|
|
PTN
57
Palatin Technologies
PTN
$18.6M
| $221K | 0.02% |
+20,500
| New | +$338K |
|
|
ADGM
58
Adagio Medical Holdings
ADGM
$11.3M
| $13.4K | ﹤0.01% |
18,444
| – | – |
|
|
ASRT
59
DELISTED
Assertio
ASRT
| – | – |
-265,707
| Closed | -$5.06M |
|
|
60
CALL
Perspective Therapeutics
CATX
$355M
| – | – |
-200,000
| Closed | -$834K |
|
|
61
Perspective Therapeutics
CATX
$355M
| – | – |
-4,675,000
| Closed | -$19.5M |
|
62
NextCure
NXTC
$27.9M
| – | – |
-141,181
| Closed | -$1.51M |
|
63
Protalix BioTherapeutics
PLX
$205M
| – | – |
-340,000
| Closed | -$738K |
|
64
Rigel Pharmaceuticals
RIGL
$868M
| – | – |
-70,000
| Closed | -$1.89M |
|
65
Sutro Biopharma
STRO
$339M
| – | – |
-190,671
| Closed | -$4.75M |
|
|
TECX
66
Tectonic Therapeutic
TECX
$696M
| – | – |
-123,000
| Closed | -$3.8M |
|
|
LBRX
67
LB Pharmaceuticals
LBRX
$1.54B
| – | – |
-14,506
| Closed | -$358K |
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q2 2026 Portfolio in Review
As of Q2 2026, Opaleye Management held 67 positions worth $1.1B, up 45% from $759M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Opaleye Management deployed $47.4M of net new capital in Q2 2026, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Immix Biopharma: 2,345,000 shares worth $24.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
On the sell side, the largest reduction was Harrow, an estimated $16.1M trimmed.
- Opaleye Management's largest Q2 2026 buy was Immix Biopharma: 2,345,000 shares worth $24.2M.
- Opaleye Management added most to Disc Medicine in Q2 2026, an estimated $29.8M increase.
- Opaleye Management's biggest Q2 2026 reduction was Harrow, cutting an estimated $16.1M.
- Opaleye Management fully exited Perspective Therapeutics in Q2 2026, selling an estimated $19.5M.
- Opaleye Management's ten largest holdings make up 65% of its $1.1B portfolio in Q2 2026.
- Opaleye Management opened 13 new positions and closed 9 in Q2 2026.
- Opaleye Management's portfolio value rose 45% quarter-over-quarter to $1.1B.
Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.